JP2004097021A

JP2004097021A - Wakame protein-containing composition, and wakame protein-containing food

Info

Publication number: JP2004097021A
Application number: JP2002259923A
Authority: JP
Inventors: Hiroshi Hagino; 萩野　浩志; Masanobu Saito; 斉藤　雅信
Original assignee: SHIRAKO KK; Shirako Co Ltd
Current assignee: SHIRAKO KK; Shirako Co Ltd
Priority date: 2002-09-05
Filing date: 2002-09-05
Publication date: 2004-04-02

Abstract

<P>PROBLEM TO BE SOLVED: To provide a composition which makes various kinds of bioactivity inherent in WAKAME genus seaweed efficiently appear. <P>SOLUTION: The WAKAME protein-containing composition is obtained by adding water, salt solution or weakly alkaline solution to thallus or dry fine-grained material each of WAKAME genus seaweed, and extracting soluble components while wet-pulverizing the mixture. The extraction with water, salt solution or weakly alkaline solution can be independently carried out to obtain each WAKAME protein-containing composition, or these extractions are successively carried out to obtain mixed WAKAME protein-containing composition. The thus obtained WAKAME protein-containing composition is used as a food effective in health because of having bioactivity such as hypotensive effect, lever function-improving function, lipid metabolism-improving function, telangiectasia function and blood viscosity-lowering function. <P>COPYRIGHT: (C)2004,JPO

Description

【０００１】
【発明の属する技術分野】
本発明はワカメ属海藻から得られたタンパク質含有組成物およびその用途としての食品に関する。
【０００２】
【従来の技術】
ワカメ属海藻は世界的に広範囲に繁殖しており、わが国においても養殖ワカメが食用として大量に消費されている。近年は食生活の変化に伴い、ワカメ属海藻の消費は減少気味であるが、他の用途への開発が進められてきている。
【０００３】
従来からワカメ属海藻は、タンパク質、食物繊維、ビタミン類、ミネラル類等の栄養成分を豊富に含み、健康に有益な食品であるといわれている。さらにワカメ属海藻は、血圧降下作用、肝機能改善作用、脂質代謝改善作用、末梢血管拡張作用、血液粘度低下作用等の生理活性を有することが指摘されている。
【０００４】
【発明が解決しようとする課題】
ワカメ属海藻が有するこれらの生理活性は、ワカメのタンパク質が胃液中の酵素ペプシンで分解されてペプチドとなり、このペプチドが中心的な役割を担っていることが明らかになった。しかしながらワカメ属海藻は強固な細胞壁を有し、さらに粘質多糖類に覆われていることから、その消化性は必ずしも高くない。また、ワカメのタンパク質がペプシンで分解される割合も低い。そのため、ワカメ属海藻の葉状体あるいは乾燥物を通常の食品形態として摂取した場合、極めて多量の葉状体あるいは乾燥物を食べなければこれらの生理活性を得ることができず、実際には効率が悪い。
【０００５】
本発明は上記情況に対処してなされたもので、ワカメ属海藻が潜在的に有する生理活性を効率よく発現させるために、そのタンパク質を調製してワカメ属海藻の有効利用を図ることを目的とするものである。
【０００６】
【課題を解決するための手段】
本発明は上記目的を達成するためになされたもので、ワカメ属海藻の葉状体または乾燥細粒化物に水または弱アルカリ水溶液を加えて湿式磨砕しながら可溶性成分を抽出し、この抽出液よりタンパク質を分離処理して得られたワカメタンパク質含有組成物に関する。また本発明は、このワカメタンパク質含有組成物を主成分とする血圧降下作用、肝機能改善作用、脂質代謝改善作用、末梢血管拡張作用および血液粘度低下作用を有する健康食品に関する。
【０００７】
前述したように、ワカメ属海藻は健康に有用な種々の生理作用を有しているが、そのものの消化性が悪いことや、含有タンパク質の体内での分解性が悪いことなどにより、実際にはこれらが有効に摂取されていない。本発明ではワカメ属海藻から効率的にタンパク質を取り出し、タンパク質成分の有用な生理活性を効率的に利用できるようにして、健康の保持、増進に役立てるようにしたものである。
【０００８】
本発明では、水、塩水溶液または弱アルカリ水溶液を用いて湿式磨砕することにより原料ワカメから高抽出率でタンパク質を抽出し、この抽出液から通常のタンパク質分離法によりワカメタンパク質を分離してワカメタンパク質含有組成物を得る。本発明で用いるタンパク質分離法としては、例えばエタノール、ポリエチレングリコールその他の有機溶剤や硫酸アンモニウムを用いるタンパク質沈殿法、イオン交換体吸着法、等電点沈殿法、膜分離法などがあり、これらを単独または併用して行うことができる。さらにワカメタンパク質の抽出率を高めるために、予めアルギン酸リアーゼ等の酵素による分解や洗浄などにより、粘質多糖類を除去しておくのもよい。
【０００９】
ワカメタンパク質含有組成物は血圧降下作用、肝機能改善作用、脂質代謝改善作用、末梢血管拡張作用、血液粘度低下作用等の生理活性を有するので、健康保持のための極めて栄養価の高い食品として有用である。
【００１０】
【発明の実施の形態】
本発明のワカメタンパク質含有組成物の製造過程を、図１を参照しながら説明する。
例えば、乾燥したワカメ粉末（１０〜５０メッシュ）２ｇに水１０ｍｌを加えてかき混ぜ、自動らいかい機を用いて室温で１時間磨砕する。次いで遠心分離機（３０００ｒ．ｐ．ｍ．）で２０分間遠心分離し、ワカメ葉体抽出残渣と上澄液とを分離する。得られた上澄液にエタノールを添加し、−２０℃で１２時間放置してタンパク質成分を沈殿させ、さらにこれを遠心分離機（３０００ｒ．ｐ．ｍ．）で２０分間遠心分離し、水可溶性ワカメタンパク質を沈殿物として得る。
【００１１】
一方、ワカメ葉体抽出残渣に塩溶液として塩化カリウムリン酸緩衝液（イオン強度＝１，ｐＨ７．５）を加えて同様に磨砕抽出し、塩可溶性ワカメタンパク質を得ることができる。さらにこの塩可溶性ワカメタンパク質の抽出残渣から、弱アルカリ性溶液として０．１Ｎ水酸化ナトリウムを加えて同様に磨砕抽出することによって、アルカリ可溶性ワカメタンパク質を得ることができる。
【００１２】
これらのワカメタンパク質は、水可溶性タンパク質、塩可溶性タンパク質、アルカリ可溶性タンパク質として別々に用いてもよいし、一緒にして用いてもよい。また、ワカメタンパク質の分離精製手段としては、上記したようにエタノールを用いるほかに、通常のタンパク質分離法、例えばポリエチレングリコールその他の有機溶剤や硫酸アンモニウムを用いるタンパク質沈殿法、イオン交換体吸着法、等電点沈殿法、膜分離法などがあり、これらを単独または併用して行うことができる。
【００１３】
次に実施例を示す。
（実施例１）
ワカメ葉状体乾燥物からの水可溶性ワカメタンパク質の調製
ワカメ葉状体を乾燥して調製した乾燥ワカメを、高速粉砕器で３５メッシュに微粉化した。この微粉末２０ｇを蒸留水４００ｍｌに混濁し、これを湿式磨砕機を用いて磨砕し、次いで遠心分離機（３０００ｒ．ｐ．ｍ．）で２０分間遠心分離し、ワカメタンパク質含有溶液１００ｍｌを得た。この溶液にエタノールを８００ｍｌ添加し、−２０℃で１２時間放置してタンパク質成分を沈殿させ、さらにこれを遠心分離機（３０００ｒ．ｐ．ｍ．）で２０分間遠心分離して沈殿物を得た。これを室温にて風乾して、水可溶性ワカメタンパク質２ｇを得た。
【００１４】
（実施例２）
塩蔵ワカメからのワカメタンパク質の調製
塩蔵ワカメを充分に脱塩後、ホモジナイザーで細片化したもの２００ｇを、０．１Ｎ水酸化ナトリウム溶液４００ｍｌに混濁して湿式磨砕機で磨砕し、これを遠心分離機（１００００ｒ．ｐ．ｍ．）で２０分間遠心分離し、アルカリ可溶性ワカメタンパク質含有溶液２５０ｍｌを得た。次に、抽出残渣を４００ｍｌの蒸留水とともに磨砕し、遠心分離機（３０００ｒ．ｐ．ｍ．）で２０分間遠心分離し、水溶性ワカメタンパク質含有溶液２５ｍｌを得た。
【００１５】
上記アルカリ可溶性ワカメタンパク質含有溶液および水溶性ワカメタンパク質含有溶液を混合し、透析膜を用いて塩類などの低分子物質を除去してタンパク質画分溶液を得、これを凍結乾燥して水およびアルカリ可溶性ワカメタンパク質４ｇを得た。
【００１６】
（試験例１）
消化試験
実施例１および実施例２で得られたワカメタンパク質各０．５ｇを、０．１％ペプシンを含む１／５０Ｎの塩酸溶液１０ｍｌに溶解させ、３７℃で３時間放置した。次に１０％炭酸ナトリウム溶液でｐＨを７．７に調整後、パンクレアチンを０．０１ｇ添加し、３７℃で２０時間放置した。次に、分子量３０００の限外濾過膜を用いて各試験液から未分解物を除去し、凍結乾燥を行ってワカメタンパク質の消化生成物を得た。
【００１７】
比較対照物として、乾燥ワカメの微粉末についてもまったく同様に、ペプシンを含む１／５０Ｎの塩酸溶液およびパンクレアチンによる消化、未分解物の除去および凍結乾燥を行い、この消化生成物を得た。
【００１８】
上記の実施例１および実施例２のワカメタンパク質から得られた各消化生成物および上記比較対照物についてそれぞれ窒素含量測定を行い、各消化前の窒素含量と比較してその％を算出した。また各消化生成物についてアンジオテンシンＩ変換酵素（ＡＣＥ）阻害活性を測定した。結果を表１に示す。
【００１９】
【表１】

【００２０】
表１に示すように、実施例１および２のワカメタンパク質の場合は、（消化生成物中の窒素）／（供試試料中の窒素）の割合は９６．５％および９０．９％であって、供試試料中の窒素の大半は消化生成物に移行しており、タンパク質の大半が消化されていることがわかるが、比較対照である乾燥ワカメ微粉末の場合は、上記窒素の割合は３３．４％であって、ほぼ２／３が消化されずに残っていることがわかる。
また、血圧降下作用を示すＡＣＥ阻害活性も、ワカメタンパク質の消化生成物の方が乾燥ワカメ微粉末の消化生成物よりはるかに強かった。
【００２１】
（試験例２）
ラットに対する血圧降下作用
実験動物として１５週齢雄性高血圧自然発症ラットを用いた。これらのラットを２週間予備飼育した後、収縮期血圧が１９０ｍｍＨｇ以上のものを選んで一群６匹とし、試験に供した。
【００２２】
実施例１で得られたワカメタンパク質および乾燥ワカメ微粉末（比較対照）のそれぞれ１０ｍｇ／ｋｇおよび３０ｍｇ／ｋｇを、ラット群に１回経口投与した。非観血的尾動脈血圧測定装置（室町機械製、ＭＫ―１０３０型）を用いてｔａｉｌ−ｃｕｆｆ法により、投与前、投与後１時間、２時間、４時間、６時間、８時間において各５回収縮期血圧を測定し、得られた測定値の最高値と最低値を棄却し、３回の平均値をもって各時間の測定値とした。結果を表２に示す。
【００２３】
【表２】

【００２４】
表２に示すように、実施例１で得られたワカメタンパク質１０ｍｇ／ｋｇ投与群は、投与後２時間から６時間の間で顕著な血圧の低下が確認された。また、このワカメタンパク質３０ｍｇ／ｋｇ投与群も、投与後１時間から顕著な血圧の低下が観察された。一方、乾燥ワカメ微粉末を投与した群は３０ｍｇ／ｋｇにて僅かな血圧の低下が観察された。
【００２５】
（試験例３）
マウスに対する血漿脂質成分濃度低下作用
実験動物として４週齢の雄性ＩＣＲ系マウスを用いた。これらのマウスを市販固形飼料で１週間予備飼育した後、７匹１群として各試験に供した。０．５％コレステロールおよび１％コール酸混入ＭＦ粉末飼料を基礎飼料として用い、対照群に基礎飼料を投与した。また試験群には、この基礎飼料に実施例２で得られたワカメタンパク質を０．３％添加したもの、同ワカメタンパク質を１．０％添加したもの、および凍結乾燥したワカメ葉体粉末を３．０％添加したもの、をそれぞれ投与した。投与は２８日間行い、試験終了後エーテル麻酔下に腹部大動脈より採血し、血漿脂質成分（総コレステロール、ＨＤＬコレステロール、トリグリセライド）の定量を行った。ＬＤＬコレステロールは総コレステロール値からＨＤＬコレステロール値を減じて求めた。結果を表３に示す。
【００２６】
【表３】

【００２７】
表３に示すように、対照群に比較してワカメタンパク質混合飼料を投与した試験群では、総コレステロール、ＬＤＬコレステロールおよびトリグリセライドの低下が認められた。一方、凍結乾燥ワカメ葉体粉末混合飼料を投与した試験群では、対照群と比較して僅かに総コレステロール等の低下が観察された。
【００２８】
（試験例４）
ラットに対するエタノール誘発肝障害保護作用
実験動物として７週齢の雄性Ｗｉｓｔａｒラットを用いた。ラットを１週間予備飼育した後、健常なラットを実験に供した。実験開始日に体重測定を行い、各群の体重の平均値がほぼ等しくなるように分散させて１群６匹とした。
【００２９】
ＭＦ粉末飼料にコレステロールおよびコール酸をそれぞれ１．０％添加したものを基礎飼料とし、３０％エタノール水を飲料水とした。試験群には、基礎飼料に実施例２で得られたワカメタンパク質を０．３％添加したもの、同ワカメタンパク質を１．０％添加したもの、および凍結乾燥したワカメ葉体粉末を３．０％添加したもの、をそれぞれ投与した。２８日間の飼育後、血清中のＧＯＴおよびＧＰＴを測定した。結果を表４に示す。
【００３０】
【表４】

【００３１】
表４に示すように、ワカメタンパク質を配合した飼料を投与した試験群は、いずれも対照群に比較してＧＯＴ値およびＧＰＴ値に顕著な低下が認められた。一方、凍結乾燥したワカメ葉体粉末を配合した飼料を投与した試験群は対照群と比較してＧＯＴ値の低下が多少認められたが、ＧＰＴ値には変化が認められなかった。
【００３２】
（試験例５）
ウサギに対する末梢血管拡張作用
実施例１で得られたワカメタンパク質を１ｇ／ｋｇ、３ｇ／ｋｇおよび１０ｇ／ｋｇ相当量、１０ｍｌの蒸留水に溶解し、カニューレを用いて固体別に１３週齢のウサギ（ニュージーランドホワイト種）に経口投与した。経口投与はウサギの耳を剃毛して血管を観察しやすくしてから行った。投与前、投与後１０分、３０分、１時間および２時間のそれぞれについて観察して写真撮影を行い、イメージングスキャナーにて血管の拡張率を計算した。比較サンプルとして乾燥ワカメ微粉末を用いて同様に行った。結果を表５に示す。
【００３３】
【表５】

【００３４】
表５に示すように、ワカメタンパク質を投与した個体は、投与前と比較して血管の拡張が観察された。一方、乾燥ワカメ微粉末を投与した個体でも血管の拡張が観察されたが、ワカメタンパク質よりも作用が弱かった。
【００３５】
（試験例６）
血液粘度低下作用
実施例２で得られたワカメタンパク質を摂取した場合の血液粘度に及ぼす影響を、ヒトについて調べた。試験前夜、Ａ、Ｂ、Ｃの３人のボランティアに肉を沢山食べてもらい、翌朝水を１００ｍｌ飲んで１時間後、予めヘパリン０．５ｍｌを加えておいた注射筒に９．５ｍｌの採血を行い、これを攪拌した後、直ちに細胞レオロジー測定装置ＭＣ−ＦＡＮＫＨ−３（日立原町電子工業（株）製）を用いて全血１００μｌの通過時間を測定した。測定後、１００ｍｌの水と共に、実施例２で得られたワカメタンパク質２ｇを経口摂取し、２時間後に同様に採血を行い、１００μｌの通過時間を測定した。結果を表６に示す。
【００３６】
【表６】

【００３７】
表６に示すように、Ａ、Ｂ、Ｃの３人とも肉を食べたことにより１００μｌの血液の通過時間は長くなったが、ワカメタンパク質を摂取した２時間後には、前日肉を食べる前の測定レベルまで回復した。
【００３８】
（実施例３）
清涼飲料水
下記の成分
実施例１で調製したワカメタンパク質　０．５重量％
砂糖　１５．５重量％
濃縮レモン果汁　１重量％
増粘多糖類　０．２重量％
ヨーグルトフレーバー　０．１重量％
水　８２．７重量％
を混合し、ボトリングした後、殺菌して、ワカメタンパク質含有清涼飲料水を製造した。
【００３９】
（実施例４）
健康補助食品
下記の成分
実施例２で調製したワカメタンパク質　７０重量％
乳糖　２９．５重量％
ショ糖脂肪酸エステル　０．５重量％
を混合し、乾式造粒した後、打錠機で打錠して錠剤とし、健康補助食品を作成した。
【００４０】
【発明の効果】
以上説明したように、本発明では、ワカメ属海藻が潜在的に有する各種の生理活性を効率よく発現させることができ、健康の保持および増進に寄与することができる。
【図面の簡単な説明】
【図１】本発明のワカメタンパク質含有組成物の製造工程の一例を示す図。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a protein-containing composition obtained from seaweed genus Wakame and a food as its use.
[0002]
[Prior art]
Seaweed genus Seaweed is widely propagated worldwide, and even in Japan, cultured seaweed is consumed in large quantities for food use. In recent years, consumption of seaweed genus Seaweed has been decreasing due to changes in eating habits, but development for other uses has been promoted.
[0003]
Conventionally, seaweed genus Seaweed is rich in nutrients such as proteins, dietary fiber, vitamins, and minerals, and is said to be a food useful for health. Further, it has been pointed out that seaweed genus Seaweed has physiological activities such as a blood pressure lowering effect, a liver function improving effect, a lipid metabolism improving effect, a peripheral vasodilatory effect, and a blood viscosity lowering effect.
[0004]
[Problems to be solved by the invention]
These physiological activities of the seaweed genus Wakame revealed that wakame proteins were degraded by the enzyme pepsin in gastric juice to form peptides, and this peptide played a central role. However, seaweed genus Seaweed has a strong cell wall, and is further covered with a mucous polysaccharide, so that its digestibility is not always high. Also, the rate of degradation of wakame protein by pepsin is low. Therefore, when the leafy or dried matter of the seaweed genus Seaweed is ingested as a normal food form, these physiological activities cannot be obtained unless extremely large amounts of the leafy or dried matter are eaten, and the efficiency is actually poor. .
[0005]
The present invention has been made in view of the above circumstances, in order to efficiently express the physiological activity potentially possessed by seaweed genus, the purpose of the present invention is to prepare a protein thereof and to effectively utilize seaweed genus. Is what you do.
[0006]
[Means for Solving the Problems]
The present invention has been made in order to achieve the above-mentioned object, and water or a weakly alkaline aqueous solution is added to the fronds or dried fine granules of seaweed genus Seaweed to extract a soluble component while wet-milling, and from this extract, The present invention relates to a wakame protein-containing composition obtained by separating a protein. The present invention also relates to a health food having a blood pressure lowering effect, a liver function improving effect, a lipid metabolism improving effect, a peripheral vasodilatory effect, and a blood viscosity lowering effect, comprising the wakame protein-containing composition as a main component.
[0007]
As described above, seaweed genus Seaweed has various physiological actions useful for health.However, due to poor digestibility of itself and poor decomposability of contained proteins in the body, it is actually These are not being taken effectively. In the present invention, proteins are efficiently extracted from seaweed genus Wakame, and useful physiological activities of the protein components can be efficiently used to help maintain and promote health.
[0008]
In the present invention, protein is extracted from raw wakame at a high extraction rate by wet grinding using water, salt aqueous solution or weak alkaline aqueous solution, and wakame protein is separated from this extract by a normal protein separation method. A protein-containing composition is obtained. Examples of the protein separation method used in the present invention include a protein precipitation method using ethanol, polyethylene glycol and other organic solvents and ammonium sulfate, an ion exchanger adsorption method, an isoelectric point precipitation method, a membrane separation method, and the like. It can be performed in combination. Further, in order to increase the extraction rate of wakame protein, the mucous polysaccharide may be removed in advance by decomposition or washing with an enzyme such as alginate lyase.
[0009]
Wakame protein-containing composition has physiological activities such as blood pressure lowering action, liver function improving action, lipid metabolism improving action, peripheral vasodilatory action, blood viscosity lowering action, etc., and is useful as an extremely nutritious food for maintaining health It is.
[0010]
BEST MODE FOR CARRYING OUT THE INVENTION
The production process of the wakame protein-containing composition of the present invention will be described with reference to FIG.
For example, 10 ml of water is added to 2 g of dried wakame powder (10 to 50 mesh), and the mixture is ground, and ground at room temperature for 1 hour using an automatic grinder. Then, the mixture is centrifuged for 20 minutes with a centrifuge (3000 rpm) to separate the seaweed leaf body extraction residue from the supernatant. Ethanol was added to the obtained supernatant, and the mixture was allowed to stand at −20 ° C. for 12 hours to precipitate a protein component. The precipitate was further centrifuged with a centrifuge (3000 rpm) for 20 minutes to obtain a water-soluble substance. The wakame protein is obtained as a precipitate.
[0011]
On the other hand, a salt-soluble wakame protein can be obtained by adding a potassium chloride phosphate buffer solution (ionic strength = 1, pH 7.5) as a salt solution to the seaweed leaf extract residue and similarly grinding and extracting. Further, from the extraction residue of the salt-soluble wakame protein, alkali-soluble wakame protein can be obtained by adding 0.1N sodium hydroxide as a weakly alkaline solution and grinding and extracting similarly.
[0012]
These wakame proteins may be used separately as a water-soluble protein, a salt-soluble protein, or an alkali-soluble protein, or may be used together. As a means for separating and purifying wakame protein, in addition to using ethanol as described above, a normal protein separation method, for example, a protein precipitation method using polyethylene glycol or another organic solvent or ammonium sulfate, an ion exchanger adsorption method, an isoelectric There are a point precipitation method, a membrane separation method and the like, and these can be used alone or in combination.
[0013]
Next, examples will be described.
(Example 1)
Preparation of water-soluble wakame protein from dried wakame fronds Dried wakame prepared by drying wakame fronds was pulverized to 35 mesh using a high-speed pulverizer. 20 g of this fine powder was turbid in 400 ml of distilled water, and this was ground using a wet grinder, and then centrifuged for 20 minutes using a centrifuge (3000 rpm) to obtain 100 ml of a wakame protein-containing solution. Was. 800 ml of ethanol was added to this solution, and the mixture was allowed to stand at −20 ° C. for 12 hours to precipitate a protein component, which was further centrifuged with a centrifuge (3000 rpm) for 20 minutes to obtain a precipitate. . This was air-dried at room temperature to obtain 2 g of water-soluble wakame protein.
[0014]
(Example 2)
Preparation of seaweed protein from salted seaweed After salted seaweed was sufficiently desalted, 200 g of a fragmented product with a homogenizer was turbidized in 400 ml of a 0.1N sodium hydroxide solution, and ground with a wet grinder. This was centrifuged for 20 minutes with a centrifuge (10000 rpm) to obtain 250 ml of an alkali-soluble wakame protein-containing solution. Next, the extraction residue was ground with 400 ml of distilled water and centrifuged for 20 minutes with a centrifuge (3000 rpm) to obtain 25 ml of a water-soluble wakame protein-containing solution.
[0015]
The above-mentioned alkali-soluble wakame protein-containing solution and water-soluble wakame protein-containing solution are mixed, and a low-molecular substance such as salts is removed using a dialysis membrane to obtain a protein fraction solution, which is lyophilized to obtain water and alkali-soluble 4 g of wakame protein was obtained.
[0016]
(Test Example 1)
Digestion test 0.5 g of the wakame protein obtained in each of Examples 1 and 2 was dissolved in 10 ml of a 1 / 50N hydrochloric acid solution containing 0.1% pepsin, and left at 37 ° C for 3 hours. . Next, the pH was adjusted to 7.7 with a 10% sodium carbonate solution, 0.01 g of pancreatin was added, and the mixture was allowed to stand at 37 ° C. for 20 hours. Next, an undegraded product was removed from each test solution using an ultrafiltration membrane having a molecular weight of 3000, and lyophilized to obtain a digested product of wakame protein.
[0017]
As a control, a fine powder of dried seaweed was digested with a 1 / 50N hydrochloric acid solution containing pepsin and pancreatin, undegraded products were removed, and lyophilized to obtain a digested product.
[0018]
The nitrogen content of each digestion product obtained from the wakame protein of Example 1 and Example 2 and the comparative control was measured, and the percent nitrogen content was calculated by comparing the nitrogen content before each digestion. The angiotensin I converting enzyme (ACE) inhibitory activity of each digestion product was measured. Table 1 shows the results.
[0019]
[Table 1]

[0020]
As shown in Table 1, in the case of the wakame proteins of Examples 1 and 2, the ratio of (nitrogen in digestion product) / (nitrogen in test sample) was 96.5% and 90.9%. Thus, it can be seen that most of the nitrogen in the test sample has been transferred to the digestion product, and that most of the protein has been digested. 33.4%, indicating that almost 2/3 remained undigested.
Also, the ACE inhibitory activity showing a blood pressure lowering effect was much stronger in the digestion product of wakame protein than in the digestion product of dry wakame fine powder.
[0021]
(Test Example 2)
Blood pressure lowering effect on rats 15-week-old male spontaneously hypertensive rats were used as experimental animals. After pre-breeding these rats for 2 weeks, those with a systolic blood pressure of 190 mmHg or more were selected to form a group of 6 rats and subjected to the test.
[0022]
Rat groups were orally administered once 10 mg / kg and 30 mg / kg of the wakame protein and the dried wakame fine powder (comparative control) obtained in Example 1, respectively. Using a non-invasive tail arterial blood pressure measurement device (Muromachi Kikai, Model MK-1030) by the tail-cuff method, 5 minutes before administration, 1 hour after administration, 2 hours, 4 hours, 6 hours and 8 hours The systolic blood pressure was measured, and the highest and lowest measured values were discarded, and the average of the three measurements was used as the measured value at each time. Table 2 shows the results.
[0023]
[Table 2]

[0024]
As shown in Table 2, in the wakame protein 10 mg / kg administration group obtained in Example 1, a remarkable decrease in blood pressure was confirmed between 2 hours and 6 hours after administration. Also, in the wakame protein 30 mg / kg administration group, a remarkable decrease in blood pressure was observed from 1 hour after administration. On the other hand, in the group to which the dried wakame fine powder was administered, a slight decrease in blood pressure was observed at 30 mg / kg.
[0025]
(Test Example 3)
4. Effect of lowering plasma lipid component concentration on mice Four-week-old male ICR mice were used as experimental animals. After pre-breeding these mice for 1 week on a commercial solid feed, they were subjected to each test as a group of 7 mice. A MF powder feed mixed with 0.5% cholesterol and 1% cholic acid was used as a basal feed, and a control group was administered the basal feed. In the test group, 0.3% of the wakame protein obtained in Example 2, 0.3% of the wakame protein obtained in Example 2, and freeze-dried wakame leaf powder were added to the basic feed. , Respectively, were administered. The administration was performed for 28 days, and after the test was completed, blood was collected from the abdominal aorta under ether anesthesia to quantify the plasma lipid components (total cholesterol, HDL cholesterol, triglyceride). LDL cholesterol was determined by subtracting HDL cholesterol from total cholesterol. Table 3 shows the results.
[0026]
[Table 3]

[0027]
As shown in Table 3, in the test group to which the wakame protein mixed feed was administered as compared to the control group, a decrease in total cholesterol, LDL cholesterol and triglyceride was observed. On the other hand, in the test group to which the freeze-dried wakame leaf body powder mixed feed was administered, a slight decrease in total cholesterol and the like was observed as compared with the control group.
[0028]
(Test Example 4)
Using ethanol-induced hepatopathy protective action <br/> 7 weeks old as an experimental animal male Wistar rats for rats. After pre-breeding the rats for one week, healthy rats were subjected to the experiment. The body weight was measured on the day of the experiment, and dispersed so that the average value of the body weight of each group was almost equal to 6 animals per group.
[0029]
A MF powder feed supplemented with 1.0% each of cholesterol and cholic acid was used as a basic feed, and 30% ethanol water was used as drinking water. The test group was prepared by adding 0.3% of the wakame protein obtained in Example 2 to the basal feed, 1.0% of the wakame protein obtained in Example 2, and 3.0% of freeze-dried wakame leaf powder. % Added, respectively. After breeding for 28 days, GOT and GPT in the serum were measured. Table 4 shows the results.
[0030]
[Table 4]

[0031]
As shown in Table 4, in the test group to which the feed containing wakame protein was administered, the GOT value and the GPT value were remarkably reduced as compared to the control group. On the other hand, the test group to which the feed containing the freeze-dried wakame leaf powder was administered showed a slight decrease in the GOT value as compared with the control group, but no change in the GPT value.
[0032]
(Test Example 5)
Peripheral vasodilator effect on rabbits The wakame protein obtained in Example 1 was dissolved in 1 g / kg, 3 g / kg and 10 g / kg equivalents in 10 ml of distilled water, and separately for 13 weeks using a cannula for each solid. Aged rabbits (New Zealand White) were orally administered. Oral administration was carried out after shaving the rabbit's ear to facilitate observation of blood vessels. Observation was performed at 10 minutes, 30 minutes, 1 hour, and 2 hours after administration before and after administration, and photographs were taken. The dilation rate of blood vessels was calculated by an imaging scanner. The same procedure was performed using dried wakame fine powder as a comparative sample. Table 5 shows the results.
[0033]
[Table 5]

[0034]
As shown in Table 5, in the individual to which the wakame protein was administered, vasodilation was observed as compared to before the administration. On the other hand, vasodilation was also observed in the individual to which the dried wakame fine powder was administered, but the effect was weaker than that of the wakame protein.
[0035]
(Test Example 6)
Blood viscosity lowering effect The effect of ingesting the wakame protein obtained in Example 2 on blood viscosity was examined for humans. The night before the test, three volunteers A, B, and C ate a lot of meat, and after drinking 100 ml of water the next morning, one hour later, 9.5 ml of blood was collected in a syringe to which 0.5 ml of heparin had been added in advance. Immediately after stirring, the passage time of 100 μl of whole blood was measured using a cell rheology measuring device MC-FANKH-3 (manufactured by Hitachi Haramachi Electronics Co., Ltd.). After the measurement, 2 g of the wakame protein obtained in Example 2 was orally taken together with 100 ml of water, and after 2 hours, blood was similarly collected, and the transit time of 100 μl was measured. Table 6 shows the results.
[0036]
[Table 6]

[0037]
As shown in Table 6, the eating time of 100 μl of blood was prolonged by eating meat of all three of A, B, and C. Recovery to measurement level.
[0038]
(Example 3)
Soft drink 0.5% by weight of wakame protein prepared in Example 1 below
Sugar 15.5% by weight
Concentrated lemon juice 1% by weight
Thickening polysaccharide 0.2% by weight
Yogurt flavor 0.1% by weight
82.7% by weight of water
After mixing, bottling and sterilization, a soft drink containing wakame protein was produced.
[0039]
(Example 4)
Dietary supplement 70% by weight of wakame protein prepared in Example 2 below
Lactose 29.5% by weight
0.5% by weight of sucrose fatty acid ester
Was mixed and dry-granulated, and then tableted with a tableting machine into tablets to prepare health supplements.
[0040]
【The invention's effect】
As described above, in the present invention, various physiological activities potentially possessed by seaweed genus Seaweed can be efficiently expressed, and can contribute to maintenance and promotion of health.
[Brief description of the drawings]
FIG. 1 is a diagram showing an example of a production process of a wakame protein-containing composition of the present invention.

Claims

Water, salt aqueous solution or weakly alkaline aqueous solution is added to the fronds or dried granules of the seaweed genus Seaweed to extract the soluble components while wet-milling, and the wakame protein content obtained by separating the protein from this extract is obtained. Composition.

The wakame protein-containing composition according to claim 1, which is obtained by sequentially performing extraction with water, an aqueous salt solution or a weakly alkaline aqueous solution.

The wakame protein-containing composition according to claim 1, wherein the method for separating the protein is a protein precipitation method using ethanol.

The wakame protein-containing composition according to claim 1, wherein the method for separating the protein is a method using a dialysis membrane.

The wakame protein-containing composition according to claim 1, wherein the method for separating the protein is a protein precipitation method using an organic solvent other than ethanol or ammonium sulfate, an isoelectric focusing method, or an ion exchanger adsorption method.

A food having a blood pressure lowering action, a liver function improving action, a lipid metabolism improving action, a peripheral vasodilatory action and a blood viscosity lowering action, comprising the wakame protein-containing composition according to claim 1 as a main component.

The food according to claim 6, wherein the food is soft drink.

The food according to claim 6, wherein the food is in the form of a tablet.